ONCO Stock Summary and Trading Ideas (Onconetix | NASDAQ:ONCO)

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Onconetix trades on the NASDAQ stock market under the symbol ONCO.

As of November 6, 2026, ONCO stock price climbed to $6.95 with 691,522 million shares trading.

ONCO has a beta of -0.52, meaning it tends to be less sensitive to market movements. ONCO has a correlation of 0.00 to the broad based SPY ETF.

ONCO has a market cap of $40.91 million. This is considered a Sub-Micro Cap stock.

ONCO has underperformed the market in the last year with a return of -99.5%, while the SPY ETF gained +10.8%. In the last 3 month period, ONCO fell short of the market, returning -23.1%, while SPY returned -4.1%. However, in the most recent 2 weeks ONCO has outperformed the stock market by returning +66.3%, while SPY returned -3.2%.

ONCO support price is $4.86 and resistance is $6.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONCO shares will trade within this expected range on the day.